Provided by Tiger Fintech (Singapore) Pte. Ltd.

PTC Therapeutics

51.26
+0.28000.55%
Post-market: 51.260.00000.00%16:44 EDT
Volume:750.74K
Turnover:38.31M
Market Cap:4.06B
PE:6.82
High:51.50
Open:49.47
Low:49.47
Close:50.98
Loading ...

PTC Therapeutics: Strong Buy Rating Backed by Promising Sepiapterin Launch and Robust Financial Outlook

TIPRANKS
·
05 Jun

RBC Raises Price Target on PTC Therapeutics to $60 From $58, Keeps Outperform Rating

MT Newswires Live
·
04 Jun

PTC Therapeutics: Promising Pipeline and Strategic Preparations Justify Buy Rating

TIPRANKS
·
04 Jun

PTC Therapeutics Unveils 2025 Corporate Presentation Highlighting Regulatory Approvals and Revenue Growth

Reuters
·
03 Jun

Citi Remains a Hold on PTC Therapeutics (PTCT)

TIPRANKS
·
03 Jun

RBC Capital views FDA flexibility on another HD drug as positive for PTC’s ‘518

TIPRANKS
·
02 Jun

PTC Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
27 May

Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), PTC Therapeutics (PTCT)

TIPRANKS
·
27 May

Mark Elliott Boulding, Executive VP and CLO, Reports Disposal of Common Shares of PTC Therapeutics Inc

Reuters
·
20 May

BofA Upgrades PTC Therapeutics to Buy From Neutral, Adjusts Price Target to $68 From $55

MT Newswires Live
·
09 May

Stock Track | PTC Therapeutics Soars 5.60% as B of A Securities Upgrades to Buy

Stock Track
·
09 May

PTC Therapeutics Raised to Buy From Neutral by B of A Securities

Dow Jones
·
09 May

PTC Therapeutics upgraded to Buy from Neutral at BofA

TIPRANKS
·
09 May

PTC Therapeutics : Barclays Cuts Target Price to $42 From $56

THOMSON REUTERS
·
08 May

Stock Track | PTC Therapeutics Soars 8.87% on Stellar Q1 Earnings and Citigroup Upgrade

Stock Track
·
07 May

Stock Track | PTC Therapeutics Soars 5% Pre-Market on Strong Q1 Earnings and Citigroup Upgrade

Stock Track
·
07 May

Stock Track | PTC Therapeutics Soars 5% Pre-Market on Strong Q1 Earnings and Analyst Upgrade

Stock Track
·
07 May

PTC Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
07 May

Citigroup Upgrades PTC Therapeutics to Neutral From Sell, Adjusts Price Target to $40 From $50

MT Newswires Live
·
07 May

PTC Therapeutics Inc : JP Morgan Cuts Target Price to $67 From $75

THOMSON REUTERS
·
07 May